August 2026Genomic alterations without approved 1L targeted therapies in patients with NSCLC PD-L1 ≥50% treated with immunotherapyPublication summaryPublicationsNon-small cell lung cancerMolecular data
August 2026Real-world outcomes with chemoradiation and durvalumab consolidation in stage III KRAS G12C-mutant NSCLC in the USPublication summaryPublicationsNon-small cell lung cancer
May 2026Real-world biomarker testing rates, targeted therapy use, and clinical outcomes in patients with advanced gastric or GEJ cancer in the United StatesPrecision medicineGastric cancer
May 2026From plenary to practice: A large language model (LLM)-based thematic analysis of landmark clinical trial discussions and factors influencing their real-world adoptionArtificial intelligence
May 2026Comparison of real-world overall survival between atezolizumab- and durvalumab-containing first- line induction and maintenance regimens in extensive-stage small cell lung cancerComparative effectivenessLung cancer
May 2026Drivers of organotropism and patterns of metastatic progression in metastatic non-small cell lung cancerLung cancer
May 2026Platinum re-challenge in platinum-resistant ovarian cancer: real-world patterns and outcomesOvarian cancer
May 2026Using ML to predict rapid progression for patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with frontline (1L) CDK 4/6 inhibitors (CDK 4/6i)Precision medicineBreast cancerArtificial intelligence